Xilio Therapeutics, Inc. — Director's Dealing 2021

Oct 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-21

Reporting Person: Huber Martin H. Jr. (President of R&D and CMO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-21	Stock Option (right to buy)	$16.00	A	157058	Acquired	2031-10-20	Common Stock (157058)	Direct

Footnotes

F1: The option award was granted on October 21, 2021 and will begin to vest on November 1, 2021 and continue to vest in equal monthly installments thereafter until October 1, 2025.